Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board
Amorfix Life Sciences Inc. announced the appointment of Mr. Michael Sonnenreich to the Company's Board of Directors.
Mr. Sonnenreich is a graduate of Harvard University Law School, the University of Wisconsin and the University of Madrid. He is the Chairman and CEO of Kikaku America International and President and CEO of Glocal Communications Corp. Ltd. of London. He is Vice Chairman of the Board of PharMa International Corporation of Tokyo, a Director of Asset Advisory Services of Zurich, an Advisor of Johns Hopkins University School of Advanced International Studies and an Overseer of Tufts University Medical School.
Mr. Sonnenreich has been a Board member and Trustee of numerous companies and universities including Scientific American Magazine, Penn Dixie Industries, ABD American Capital Market Funds, the Integra Fund, Medical Tribune International, Continental Steel Inc, Clark University, the Maret School and the Washington National Opera (President). He was President of the National Coordinating Council on Drug Education.
Amorfix also announced the formation of a Scientific Advisory Board (SAB) led by Dr. Neil Cashman, Chief Scientific Officer for Amorfix, who will step down from the Board of Directors to Chair the SAB. Joining Dr. Cashman is an expert in ALS and motor neuron diseases, Dr. Don Cleveland.
Dr. Cleveland received his doctorate from Princeton and was a professor at Johns Hopkins University School of Medicine prior to accepting his current position at the Ludwig Institute at University of California, San Diego, where he is currently director of the laboratory of cell biology. He has published extensively on adult motor neuron diseases, such as Amyotrophic Lateral Sclerosis, or ALS, the hallmark of which is the selective death of motor neurons. He is an Editor of the Journal of Cell Biology.
Other news from the department people
